Bone Drug Zometa Flops Overall as Breast Cancer Treatment

(5 stars)
When something doesn’t work, say so. That’s what this story did, unlike the Los Angeles Times story we also reviewed about the negative results from the AZURE trial that looked for survival differences when zoledronic acid (Zometa) was added to standard therapy for women with early stage breast cancer.